Robert D. Toto

TL;DR: Angiotensin-converting enzyme inhibitors appear to be more effective than beta-blockers or dihydropyridine calcium channel blockers in slowing GFR decline in hypertension.

TL;DR: Patients undergoing hemodialysis thrice weekly appear to have no major benefit from a higher dialysis dose than that recommended by current U.S. guidelines or from the use of a high-flux membrane.

TL;DR: An evidence-based approach is provided, integrating data from the major clinical trials that were designed as randomized prospective, long-term studies that had as a primary endpoint either progression of diabetic nephropathy or reduction in CV events to achieve lower blood pressure goals.

TL;DR: This meta-analysis showed that systolic blood pressure and urinary protein excretion were related to the risk for renal disease progression in patients with nondiabetic kidney disease.

TL;DR: A large number of patients in the pooled analysis would provide sufficient statistical power to detect relationships between patient characteristics and risk for progression of renal disease and interactions of patient characteristics with treatment effect, and strong and consistent results from analysis would clarify the effects of ACE inhibitors for treatment of nondiabetic renal disease.